User profile
Select your user profile
Article

Creating complex and reliable tissue multiplexing assays

Kevin Lagan headshot

 

 

 

Kevin Lagan, Product Manager at Roche Diagnostics UK & Ireland, explains the challenges researchers face and how the Roche Diagnostic portfolio of tools, technologies and solutions can tackle them.

Roche Diagnostic technologies like the DISCOVERY ULTRA instrument can enable the creation of complex, consistent and reliable tissue multiplexing assays to accelerate research.

What do you believe are the key challenges in tissue-based research?

Reliabilityconsistency and cost-effectiveness are key challenges at the moment – especially for those involved in high-throughput research. Laboratories are under increasing pressure to accelerate results, which drives the demand for innovative technologies and streamlined workflows.

On the technical side, we’re seeing a greater interest in automation and the adoption of more advanced research techniques to power discoveries. Laboratories prefer partnering with technology providers to achieve their research goals, including streamlining workflows and implementing scalable solutions.

Chose the right method

How can Roche research technologies help researchers?

Chose the right method

Our technology is designed to help researchers overcome some of the key challenges in tissue diagnostics. As one of the leading innovators in tissue diagnostics, we offer a comprehensive and open portfolio of technologies and software tailored to meet their needs. One of the standout features of the DISCOVERY ULTRA instrument is its ability to enable multiplexing.

Instead of being limited to analysing one or two biomarkers, researchers can investigate up to eight different markers within a single tissue specimen. This capability allows them to uncover deeper insights into tissue biology faster than traditional single plex DAB testing. Our platform utilises differentiated properties of Roche ready to use chromogens, such as translucence, to visualise co-localised markers within the tissue more effectively. This enables more comprehensive visualisation of the spatial relationships between multiple biomarkers, improving diagnostic accuracy.

The DISCOVERY ULTRA instrument also supports immunofluorescence, giving researchers the flexibility to use fluorescent detection alongside traditional brightfield microscopy. Immunofluorescence enables the detection of multiple markers within the same tissue specimen. Researchers can spectrally deconvolute these markers by switching fluorescent channels, allowing for precise identification and localisation.

You say that Roche technologies are open. What does this mean?

We don’t want to lock scientists into a system or limit their research, so Roche software is designed to integrate seamlessly with third-party solutions, offering open automation capabilities. This ensures that researchers can incorporate their preferred tools into their workflow, enhancing productivity and customisation.

For example, customers can use third-party primary antibodies and third-party detection chemistries if they choose to. Some of our customers use third-party immunofluorescence solutions as well.

As a trusted partner, we work with all lab customers to identify a solution suitable for their labs and existing research processes. Together, we can develop a combination of Roche and third-party tools, technologies and supporting software and systems that accelerate discovery.

Chose the right method

What kind of research organisations does Roche work with?

Chose the right method

We work with labs engaging in high-throughput research activities. You need the scale to make the best use of Roche technologies like the DISCOVERY ULTRA instrument.

We collaborate with pharmaceutical companies of all sizes on drug discovery and toxicology studies. We deliver the expansive menu and consistent quality you need to deliver the highest level of patient care and DISCOVERY continues to bring immense value to early biomarker and companion diagnostic identification efforts for our pharma partners. We also serve the contract research organisation community, supporting them in their work. In these instances, Roche technologies are helping them to test at scale.

For example, they may be taking an assay and seeking to transfer it from a research environment into an industrial scale. We can support this with a mass-testing solution that enables them to gather vital statistical data to support the biomarker discovery pathway.

What are the benefits of working with Roche?

We know that each lab is different, and no two solutions are the same. When you work with Roche, you’re engaging an experienced partner who understands your challenges.

Our approach is to create a solution built around your lab, your staff and your research challenges. We provide software and support to integrate the latest testing technologies into your lab, as well as the latest testing technologies.

Customers benefit from reliable and robust technology and experience a level of service that ensures total confidence and trust.

Chose the right method

This Q&A is taken from a more extended interview with Kevin Lagan conducted by Roche Diagnostics UK & Ireland (data on file). The views shared in this article represent the views and opinions of the original speaker and do not necessarily represent the views of Roche Diagnostics UK & Ireland.

Researcher face with glasses smiling

Roche Research Solutions

Advancing research and empowering discoveries

Roche provides researchers with leading innovations for genome sequencing, tissue staining, microarray analysis, nucleic acid purification, cell analysis and real-time qPCR. Working with you, we’ll streamline implementation and accelerate discovery in your lab.